重组痘苗病毒乙肝基因工程疫苗对乙肝母婴传播阻断的研究

Prevention of Transmission of HBV from Mother to Baby by Recombinant Vaccinia Virus HB Gene Vaccine

重组痘苗病毒乙肝基,因工程疫苗首次用于母婴乙肝传播阻断。该疫苗对e-抗原阳性母亲所生新生儿,用20μg剂量0、1、6,3针免疫计划,抗乙肝病毒携带的保护率T_7和T_(12)均为82.1％,与30μg剂量血源疫苗比较T_7和T_(12)保护率分别是85.8％和88％,两者无差异。基因苗T_3为81.2％。T_7和T_(12)测抗-HBs阳性率均为84.8％,miu/ml值分别为280.3和230.6;而血源苗T_7和T_(12)抗-HBs阳性率为81.6％和87.7％,miu/ml值为127.7和129.8,而T_3时基因苗已有84.6％的人产生了保护性抗体。

Interruption of mother to baby HBV transmission by recombinant vaccinia was carried out for first time at home and abroad. The total 33 cases of infant who born by HBeAg positive mothers was vaccinated with 20μg/dose recombinant vaccine at 0, 1 ,6 months. Interruption rate of the vaccine for HBV transmission was 82.1% in seventh and twelveth month, as comparison, interruption rate of 30μg/dose of plasma derived HB vaccine was 85.8% and 88.0%. It was no statitically significant in both vaccine (p>0.05). Protective rate of recombinant anti-HBs positive rate of recombinant vaccine was 84.8% in Seventh and twelveth month. Miu/ml value were 280.3 and 230.6.These of the plasma derived HB vaccine were 81.6% and 87.67%, and their Miu/ml value were 127.7 and and 129.8. The anti-HBs conversion rate of recombinant vaccine was 84.6% in third month.